Article Detail

Home > Article Detail
  • P-ISSN 1010-0695
  • E-ISSN 2288-3339

Prev

Next

Vol.42, No.1
Citation Share

Case Report on Complete Response and 5 year Survival of Non-Small Cell Lung Cancer IIIB Patient Treated with Integrative Medicine

Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2021, v.42 no.1, pp.119-128
https://doi.org/10.13048/jkm.21009









& (2021). Case Report on Complete Response and 5 year Survival of Non-Small Cell Lung Cancer IIIB Patient Treated with Integrative Medicine. Journal of Korean Medicine, 42(1), 119-128, https://doi.org/10.13048/jkm.21009
  • Downloaded
  • Viewed

Abstract

Objectives: This is a five-year survival case report on non-small cell lung cancer (NSCLC) treated with western medicine and traditional Korean medicine. 44-year old man diagnosed NSCLC IIIB in 2015 went through two months' concurrent chemoradiotherapy (CCRT) first, however the cancer did not response. After CCRT he began to take intensive integrative therapy including acupuncture, abdominal moxibustion, wild ginseng pharmacopuncture, herbal medicinal product of ginseng, hyperthermia, Thymosin α1, and mega vitamin C injection for 4 years and 9 months. After three months of intensive treatment, the state of cancer changed first to partial response and then complete response. He finally succeeded in five-year survival without any recurrence or complication in 2020, We suggest that integrative approach including traditional Korean medicine can be a meaningful treatment option for nonoperable NSCLC. Further studies with more cases should be performed to establish proper treatment protocol of integrative medicine for lung cancer.

keywords
Non-Small Cell Lung Cancer, Concurrent Chemoradiotherapy, Traditional Korean Medicine, Integrative Medicine


Reference

1

1. Annual Report of national cancer statistics in Korea in 2017. National Cancer Center. 2019.

2

2. Jeong SH, Jung JH, Lee HW, Kang SY, choi YW, Ahn MS, et al. Concurrent Chemoradiotherapy with Weekly Paclitaxel for Locally Advanced Non-small Cell Lung Cancer. J Lung Cancer. 2009;8(1);8-12.

3

3. Wu X, Chung VC, Lu P, Poon SK, Hui EP, Lau AY, et al. Chinese Herbal Medicine for Improving Quality of Life Among Nonsmall Cell Lung Cancer Patients: Overvies of Systematic Reviews and Network Meta-Analysis. Medicine. 2016;95(1):e2410.

4

4. Liu J, Lin HS, Hou W, Hua BJ, Zhang PT, Li J, et al. Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study. Chin J Integr Med. 2017;23(10):733-739.

5

5. Han GJ, Cho MJ, Park EJ, Seong S, Kim SS, Kim KI, et al. Analysis of existing guidelines and randomized, controlled, clinical trials for development of [guideline of clinical trial with herbal medicinal product for lung cancer]. J Korean Med. 2019;40(1):153-173.

6

6. Jung HJ, Kim JD. The Role of Korean Medicine for Treatment and Management for Lung Cancer. J Kor Trad Oncol. 2015;20(1):45-54.

7

7. Kin KS. Case Study: Regression of a residual tumor and prolongation of overall survival with allergen-removed Rhus Verniciflua stokes after chemoradiotherapy in locally advanced non-small cell lung cancer. J Int Korean Med.2015;36(2):200-206.

8

8. Park SJ, Kang HJ, Park JH, Cho CK, Yoo HS. A case report of a clinically diagnosed advanced lung cancer patient after treatment with Gunchilgyebok-Jung. J Kor Trad Oncol. 2015;20(1):23-29.

9

9. Zheng HM, Yoon JW, Lee YW, Cho CK, Ph DS, Yoo HS. Case Series of advanced non-small cell lung cancer patients treated with Hang-am Plus. J Int Korean Med. 2011;32(1):113-120.

10

10. Park SJ, Kim SY, Cho CK, Jung IC, Yoo HS. Preliminary study to develop the instrument of oriental medical evaluation for lung cancer. J Korean Med. 2015;36(3):53-64.

11

11. Park JG, Bang YJ, Ha SH. Oncology. 2nd rev. ed. Seoul:Iljogak. 2012:224-239.

12

12. NCCN clinical practice guidelines in oncology (ver.8). National Comprehensive cancer network. 2020.

13

13. Costa GJ, Ferreira CG, Thuler CS. Concurrent chemoradiotherapy for stage III non-small cell lung cancer: corredt clinical management as the basis to move beyond, Ann Transl Med. 2018;6(Suppl 1):S65.

14

14. Lee JC, Yun HY, Yoo HS, Bang SH. A case report of complete response of advanced gastric carcinoma patient treated with Korean medicine treatment in conjuction with chemoradiation therapy. J Kor Trad Oncol. 2014;19(1):25-32.

15

15. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3(8):487-497.

16

16. Garaci E, Pica F, Matteucci C, Gaziano R, D'Agostini C, Miele MT, et al. Historical review on thymosin α1 in oncology: preclinical and clinical experiences. Expert Opin Biol Ther. 2015;15(Suppl 1):S31-9.

17

17. Fritz H, Flower G, Weeks L, Cooley K, Callachan M, McGowan J, et al, Intravenous Vitamin C and Cancer: A Systematic Review. Integr Cancer Ther. 2014 Jul;13(4):280-300.

18

18. Kwon KR, Kim HD, Kim JS, Yoo HS, Cho CK. Case series of Non-small cell Lung cancer treated with mountain Ginseng pharmacopuncture. J Acupunct Meridian Stud. 2011;4(11):61-68.

19

19. Dai D, Zhang CF, Williams S, Yuan CS, Wang CZ. Ginseng on Cancer: Potential Role in Modulating Inflammation-Mediated Angiogenesis. Am J Chin Med. 2017;45(1): 13-22.

  • Downloaded
  • Viewed
  • 0KCI Citations
  • 0WOS Citations

Other articles from this issue

Recommanded Articles

상단으로 이동

Browse Articles

Info

Editorial policy

Bulletin Board

COPYRIGHT ⓒ 2018 한국기록관리학회지.07525 91, Heojun-ro, Gangseo-gu, Seoul, Korea;Third floor 307 Tel : 02-2658-3627 Fax : 02-2658-3631 email : skom1953@daum.net

  This website recommended the use   the Chrome browser for journal website.

Journal of Korean Medicine

e-Submission OA Policy